Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Overview

This article discusses the development of a cellular thermal shift assay in a 384 well format to assess target engagement of SHP2 inhibitors in intact cells. The focus is on both wild-type SHP2 and its oncogenic variants, which are crucial for effective drug discovery in cancer therapy.

Key Study Components

Area of Science

• Cellular signaling
• Cancer therapy
• Drug discovery

Background

• SHP2 is a tyrosine phosphatase involved in promoting cell survival and proliferation.
• Inhibiting SHP2 has potential therapeutic benefits in cancer treatment.
• Several SHP2 inhibitors are currently in clinical trials.
• Target engagement assessment is vital for directing discovery resources efficiently.

Purpose of Study

• To establish a reliable method for detecting cellular target engagement of SHP2 inhibitors.
• To facilitate the identification of effective small molecule inhibitors.
• To enhance the efficiency of drug discovery processes.

Methods Used

• 384 well format cellular thermal shift assay.
• Assessment of target engagement in intact cells.
• Evaluation of both wild-type and oncogenic variants of SHP2.
• Rapid screening of small molecule inhibitors.

Main Results

• The assay reliably detects target engagement of SHP2 inhibitors.
• Demonstrated effectiveness in both wild-type and oncogenic variants.
• Provides a powerful method for drug discovery in cancer therapy.
• Supports the efficient allocation of research resources.

Conclusions

• The developed assay is a valuable tool for assessing SHP2 inhibitors.
• It enhances the understanding of SHP2 as a target in cancer therapy.
• This method can streamline the drug discovery process for SHP2 inhibitors.

Frequently Asked Questions